Radiotherapy with twice weekly Gemcitabine and Cisplatin compared to Cisplatin alone for organ preservation in muscle-invasive bladder cancer: results of the GETUG V04 randomized phase II trial.

Fiche publication

Date publication

février 2026

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr QUIVRIN Magali

Tous les auteurs :
Michalet M, Ronchin P, Reynaud T, Demogeot N, Gourgou S, Thézenas S, Hannoun-Lévi JM, Salem N, Quivrin M, Riou O, Charissoux M, Llacer-Moscardo C, Tosi D, Durdux C, Khalladi N, Culine S, Azria D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41690405

Résumé

Trimodal therapy (TMT) is a viable option for muscle-invasive bladder cancer (MIBC), but the optimal chemotherapy regimen remains unclear. This phase II randomized trial (NCT01495676) compared cisplatin (CDDP) with twice-weekly gemcitabine (GEM) and radiation therapy (RT) with CDDP plus RT.